Stefănescu I
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol. 1976 Oct-Dec;25(4):201-8.
An attack treatment with 3 drugs during 4-6 months and a consolidation treatment with 2 drugs then INH was applied in 595 cases detected between July 1, 1968 and June 30, 1972, i.e. 264 group A (positive), 200 group B (negative cultures) and 131 group C (pleuretics). The contacts had been in close contact with the source for at least three months before establishing the diagnosis; 549 had been vaccinated at birth with BCG and 209 revaccinated; 413 had undergone chemoprophylaxis with INH. The control group comprised 1008 subjects, the mean age of the groups being very close; they were followed up for 2 years and 1 month and 2 years and 7 months. Testing was done every year with 1 u PPD IC 65. The contacts were controlled annually by radiophotography and X-ray and the controls only in case of shifting of the test. Among the contacts there were 44 conversions in the subjects with an initial tuberculin reaction of 0-5 mm and 4 in those with an initial tuberculin reaction of 6-9 mm, representing 15.1% (group A 27.7%, group B 9,8%, group C 10.5%). Three months after the initiation of chemotherapy the proportion of conversions in the three groups (group A 12.3%, group B 5.9%, group C 10.5%) was equal to that of the controls (8.8%). The next year there were 11.2% conversions among the contracts (group A 11.4%, group B 9.6% and C 17.7%) as against 11.9% among the controls. In the first year 8.3% of the contacts contracted tuberculosis (A 15.6%, B 2.4%, C 4.0%) and 0.32% of the controls. The next year 2.8% of the contacts fell ill (A 4.3%, B 2%, C 0%) and 0.5% of the controls. Among group A contacts aged 0 to 6 years there were 31.7% conversions and 30.7% cases of tuberculosis in the first year, and 7.1% and 1.8% respectively in the following year. Group B and C presented 10.9% conversions and 6% cases of disease in the first year, and no case of tuberculosis in the second year. Chemotherapy reduced conversions and sickness in this group three months after the diagnosis was established.
1968年7月1日至1972年6月30日期间确诊的595例患者采用了为期4 - 6个月的3药联合强化治疗及之后的2药联合巩固治疗，随后使用异烟肼。其中，A组（阳性）264例，B组（培养阴性）200例，C组（胸膜炎患者）131例。接触者在确诊前与传染源密切接触至少3个月；549例出生时接种过卡介苗，209例进行了复种；413例接受过异烟肼化学预防。对照组有1008名受试者，两组平均年龄非常接近；对他们进行了2年1个月和2年7个月的随访。每年用1单位PPD IC 65进行检测。每年对接触者进行放射摄影和X线检查，对照组仅在检测结果出现变化时进行检查。在接触者中，初始结核菌素反应为0 - 5毫米的受试者中有44例发生血清转化，初始结核菌素反应为6 - 9毫米的受试者中有4例发生血清转化，占15.1%（A组27.7%，B组9.8%，C组10.5%）。化疗开始3个月后，三组（A组12.3%，B组5.9%，C组10.5%）的血清转化比例与对照组（8.8%）相当。次年，接触者中有11.2%发生血清转化（A组11.4%，B组9.6%，C组17.7%），而对照组为11.9%。第一年，8.3%的接触者感染结核病（A组15.6%，B组2.4%，C组4.0%），对照组为0.32%。次年，2.8%的接触者患病（A组4.3%，B组2%，C组0%），对照组为0.5%。在0至6岁的A组接触者中，第一年血清转化率为31.7%，结核病发病率为30.7%，次年分别为7.1%和1.8%。B组和C组第一年血清转化率为10.9%，疾病发病率为6%，次年无结核病病例。确诊后3个月，化疗降低了该组的血清转化率和发病率。
